Cutaneous melanoma has been suspected to be influenced by female hormones. Several studies reported a positive association between oral contraceptive (OC) use and melanoma risk. However, findings were conflicting and data from large prospective studies are lacking. E3N is a prospective cohort of 98,995 French women aged 40-65 years at inclusion in 1990. Exposure to lifetime OC use was assessed in 1992 and through biennial questionnaire updates. To assess the association between OC use and melanoma risk, we used Cox models adjusted for age, pigmentary traits, residential ultraviolet (UV) exposure in county of birth and at inclusion and family history of skin cancer. Over 1992-2008, 539 melanoma cases were ascertained among 79,365 women. In age-adjusted models, we found a modest positive association between ever use of OCs and melanoma risk (hazard ratio (HR) = 1.18, 95% confidence intervals (CIs) = 0.98-1.42), which was reduced after adjustment (HR = 1.14, 95% CI = 0.95-1.38). The association was stronger in long-term users (duration 10 years: HR = 1.33, 95% CI = 1.00-1.75) and in women who used high-estrogen OCs (HR = 1.27, 95% CI = 1.04-1.56). Among users, there was an inverse association with age at first use (p trend < 0.01), but no evidence of an association with age at last use or time since last use. OC use was positively associated with tanning bed use (OR = 1.14, CI = 1.01-1.29), sunburns (ptrend = 0.5) and sunscreen use (OR = 1.13, CI = 1.00-1.28) since age 25. Overall, our findings do not support a strong association between OC use and melanoma risk and suggest intentional UV exposure in OC users, which supports a potential confusion by UV exposure in this relationship.
Introduction
Evidence suggests that cutaneous melanoma, the most lethal form of skin cancer, may be influenced by sex hormones. The hypothesis was based on several observations: the known influence of sex hormones on pigmentation and melanocytic tumors; 1 the occurrence of melasma and changes in nevus size and pigmentation during pregnancy; 2,3 the suggested progression of melanoma and worse prognosis among pregnant women; [4] [5] [6] [7] the reported associations between reproductive factors 8 or hormone use [9] [10] [11] [12] and melanoma risk; a higher incidence of melanoma among women compared with men in Europe; 13 and the observed "female advantage" with regards to melanoma survival, women being consistently reported to have better survival rates, 14 lower risks of metastasis 15 and lower mortality rates for melanoma than men, 16, 17 regardless of body site, histological type or tumor stage. 14, 18 Oral hormones are the leading contraception method in industrialized countries, and they represent a significant source of exogenous hormone use. 19 In France, women started to use estrogens and progestogens for contraception in the 1960s, before it was even marketed for this indication. In 1970, when oral contraception started to be legally supervised in France, its use was already rising in the population, with 600,000 users. In 1972, it reached 1,200,000 users, and sales continued to rise. 20, 21 Numerous types of pills have been marketed since then: doses of ethinyl estradiol (EE) progressively diminished, alternative regimens of administration appeared, with bi-or tri-phasic preparations including progestogens to mimic natural cycles, and several generations of less androgenic associated progestogens followed.
Oral contraceptive (OC) use has been inversely associated with ovarian, endometrial and colorectal cancer incidence. 22 However, it has also been positively associated with the risks of breast, cervical and liver cancers. 22 As a result, oral estrogen-progestogen contraceptives have been classified as carcinogenic to humans (Group 1) by the International Agency of Research on Cancer in 2007. 19 The relation between OC use and cutaneous melanoma risk has been investigated in 7 cohort and 21 case-control studies to date, as analyzed in 3 meta-analyses. [23] [24] [25] These meta-analyses did not show consistent evidence for an association between OC use and melanoma risk, considering either current use, duration of use, time since last use or age at first use; however, there was a high level of heterogeneity in the included studies. 23 The reported associations between reproductive factors and melanoma risk in women have been proposed to be related to different sun exposure behaviors between sexes rather than sex hormones. 26, 27 However, few studies investigating hormonal exposures took sun exposure into account, and none of the previous investigations tested a potentially different effect of OC use on melanoma risk according to sun exposure.
Moreover, although melanoma is a heterogeneous tumor, 28 with one specific pathway linked to chronic sun exposure, very few studies explored the potential associations between OC use and melanoma risk according to anatomic site or histologic type of the tumor.
In view of the limited available evidence, more research is warranted in order to clarify the associations between OC use and melanoma risk in women. Our aim was to explore these associations and to investigate potentially differential effects by sun exposure level and tumor characteristics, in a large prospective cohort of French women.
Materials and Methods
The E3N cohort E3N (Etude Epidémiologique auprès de femmes de l'Education Nationale) is an ongoing prospective cohort study involving 98,995 French women born in 1925-1950 and insured by a national health scheme covering workers from the French National Education System and their families. Women were enrolled in 1990 after returning a baseline self-administered questionnaire on their lifestyle and medical histories along with an informed consent. Follow-up questionnaires were sent every 2-3 years thereafter and addressed medical events such as cancer, which were confirmed through pathology reports. The E3N cohort received ethical approval from the French National Commission for Data Protection and Privacy (Commission Nationale Informatique et Libertés [CNIL]).
Data collection
Assessment of OC use. Use of oral hormones for contraception was collected at baseline and detailed information on lifetime OC use was recorded in the 1992 questionnaire, which collected the start date and duration of each episode of hormone use, together with the corresponding brand names. To facilitate reporting, the 1992 questionnaire included a booklet with an extensive list and color pictures of the treatments marketed in France. This information was then updated in each follow-up questionnaire.
OCs were either combined estrogens and progestogens, progestogen-only, or of unknown hormone type. We classified combined formulations by dose of estrogen, as high (50 μg of EE), moderate (30-40 μg of EE), low (<30 μg of EE) or unknown. OCs containing 50 μg of mestranol were considered with a moderate dose of estrogen, 50 μg of mestranol being bioequivalent to 35 μg of EE, its active metabolite. 29 We also examined types of progestogen by distinguishing derivatives of estrane, gonane, pregnane, spironolactone or unknown.
Assessment of ultraviolet (UV) exposure. To estimate childhood and baseline residential ultraviolet radiation exposure among participants, counties of birth and of residence as collected at baseline were linked to a European database containing mean daily UV radiation doses in French counties. 30 In a sub-population, the E3N-SunExp nested case-control study, detailed information was collected on lifetime residential and recreational UV exposures. 31 Briefly, in 2008, a specific questionnaire on UV exposure was sent to all incident skin cancer cases and three controls per case (matched on age, county of birth, education and duration of follow-up in the cohort). The sub-cohort included 1,558 skin cancer cases and 3,647 matched controls; women were asked to complete lifetime diaries of residence and holiday locations, with information on time spent in the sun and sun protection for each location. Data were linked to an international database on average daily UV doses, 32, 33 which was used to calculate What's new? Evidence suggests that cutaneous melanoma is influenced by female sex hormones. However, whether oral contraceptives, a major exogenous source of female hormones, are associated with melanoma remains unclear. In the present prospective cohort study, which included data on more than 79,000 French women, melanoma risk was associated with long-term oral contraceptive use and the use of high-dose estrogen oral contraceptives. Oral contraceptive users, however, were more likely to have used tanning beds and were more likely to report higher numbers of sunburns than non-oral conceptive users, suggesting that intentional ultraviolet exposure influenced the observed increase in melanoma risk.
total, residential and recreational UV scores. The questionnaire also collected data on number of sunburns and sunscreen use at ages <15, 15-25 and > 25 years and lifetime tanning bed use.
Assessment of other factors. Pigmentary characteristics were collected at baseline and included hair color (red, blond, light brown, dark brown and black), skin complexion (very fair, fair, medium, dark and very dark), number of nevi and number of freckles (none, few, many and very many), and skin sensitivity to sun exposure (low, moderate and high). Family history of skin cancer in first-degree relatives was collected in 2000. Age at menarche, parity and use of infertility drugs were collected in 1990 and 1992. The 1992 questionnaire also inquired about menstrual cycle length during midlife. Information about lifetime use of menopausal hormone therapy (MHT) and premenopausal progestogens was requested in 1992 and then updated in subsequent questionnaires. Each questionnaire inquired about Pap smears performed since the last returned questionnaire, and we used this information as a proxy for gyne- 
Analysis populations and follow-up
Women who did not return the 1992 questionnaire (n = 12,827), those who were lost to follow-up from the 1992 questionnaire (n = 1,850), those with aberrant OC use data (i.e., start date after menopause onset) (n = 182), users of an injectable contraceptive (n = 45), women who reported a history of cancer other than basal-cell carcinoma at baseline (n = 4,698) and those who reported primary amenorrhea (n = 28), were excluded. Our final sample for analysis consisted of 79,365 women.
Follow-up started at the date of return of the 1992 questionnaire. Participants contributed person-time until the date of melanoma diagnosis, date of diagnosis of any other cancer (except basal-cell carcinoma), date of last questionnaire returned or date of end of follow-up (July 2008), whichever occurred first.
Sensitivity analyses adjusting for sun exposure behaviors were performed within the E3N-SunExp subpopulation, considering only melanoma cases (n = 366) and their matched controls (n = 852). Within this population, we additionally analyzed the relations between OC use and sun exposure behaviors in the 4,196 women included as controls in the study.
Statistical analyses
Statistical analyses were performed using the SAS statistical software package (version 9.4). We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) using Cox proportional hazards regression models with age as the time scale. Associations between OC use and melanoma risk were first assessed in age-adjusted models, stratified on year of birth (in 5-year categories), then in models additionally adjusted for pigmentary traits (hair and skin color, sensitivity to sun exposure, number of nevi and freckles), residential UV exposure in county of birth and at inclusion and family history of skin cancer. In subsequent separate models, we performed additional adjustment for height (continuous), BMI (<18.5, 18.5-22.4, 22.5-24, 25-29 and 30 kg/m 2 ), parity (nulliparous, <3 and 3 children), menopausal status (pre-or postmenopausal), ever use of other hormonal treatments (MHT, premenopausal progestogens and infertility drugs), menstrual parameters (age at menarche, menstrual cycle length), gynecologic follow-up (Pap smear test reported in all returned questionnaires: yes or no) income (quartiles), education (<12 years, 12-15 years, 15 years), marital status (in a relationship, single, separated, widowed), and smoking (ever, never). Ever use of OC, age at last use, time since last use and duration of use were considered as time-dependent variables, as well as menopausal status and MHT use. However, we also checked the stability of the results using baseline characteristics only. Tests for linear trend were performed using an ordinal score for each quartile. Each OC type was considered in non-mutually exclusive categories, as most women took several OCs. Types of OCs were analyzed in models adjusted for the use of any other formulation; we excluded the only participant using an OC with a spirolactone derivative.
To further assess the association between duration of OC use and melanoma risk, we performed restricted cubic regressions based on the Cox proportional hazards regression. We used the RCS SAS Macro with duration of OC use at end of follow-up as a continuous variable, using 4 knots corresponding to quartile groups among users and a null duration as reference. 34 The model was adjusted for year of birth, age at inclusion, pigmentary traits, residential UV exposure and family history of skin cancer.
We analyzed melanoma risk according to anatomic site and histologic subtype using competing-risk models with the cause-specific hazards approach. 35, 36 Cases with missing information on anatomic site (n = 45) or histologic subtype (n = 29) were excluded from these analyses. Tests for homogeneity using Chi-square tests were performed to compare estimates over strata.
We tested for effect modification by socioeconomic factors (income, occupation, education and marital status) use of other hormonal treatments, pigmentary traits, and height, using interaction tests.
Analyses in E3N-SunExp were performed through logistic regression modeling: associations between OC use and melanoma risk were investigated using conditional logistic regression, considering the matched triplets of cases and controls, adjusting for recreational sun exposure; unconditional logistic regression adjusted for age and year of birth was performed when exploring associations between sun exposure and OC use in controls. We investigated effect modification by sun exposure of the relation between OC use and melanoma risk and by pigmentary traits of the relation between sun exposure and OC use in controls.
Women with missing data for OC exposure factors were excluded separately in each factor; figures are provided as footnotes in Table 2 . For adjustment variables, missing values were imputed to the median or to the modal category if occurring in <5% of observations; 37 otherwise a missing category was created.
RESULTS
Over 966,604 woman-years of follow-up, 539 melanoma cases were ascertained among the 79,365 included women (median follow-up: 13.4 years).
Overall, compared with never-users, OC users were younger, had higher education levels and were more likely to belong to the highest quarter of the cohort in terms of income (Table 1 ). They were more likely to be in a relationship, to be parous and to have used other hormonal treatments (premenopausal progestogens or MHT). OC users were also more likely to report higher height and to have ever smoked. They were slightly more likely to report higher numbers of nevi and freckles and more likely to report frequent gynecologic follow-up.
The mean cumulative duration of OC use was 7.3 years ( Table 2 ). The mean age at start of use was 28.7 years. At inclusion, most OC users were past users (78%), consistently with a mean age at last use of 38.2 years. Most users reported the use of several types of OCs in their lifetime (63%). A majority of users reported the use of a combined OC with high doses of estrogen (50 μg of EE; 58%) or with a gonane derivative (60%). The distribution of OC types ever used according to birth cohort shows that combined OCs with high doses of estrogens were the most used types of OCs and that its use increased across generations.
Compared with never use, ever use of OC was associated with a modest increase in melanoma risk in the age-adjusted model (HR = 1.18, CI = 0.98-1.42) and the relation was slightly reduced after adjustment (HR = 1.14, CI = 0.95-1.38) (Table 3 ). However, women who used OCs for 10 years or more over their lifetime had a higher risk of melanoma compared with never users and the association was stable after adjustment (HR = 1.33, CI = 1.00-1.75; p trend = 0.06). A cubic spline regression confirmed a higher melanoma risk with increased duration of OC use, particularly after 7 years of use ( Figure 1 ). Among OC users, we found a positive association with duration of use (HR = 1.02, CI = 1.00-1.04 for each additional year of use). There was an inverse association between age at first OC use and melanoma risk among users (p trend < 0.01), consistent with a negative correlation between age at first use and duration of use (r = −0.23). However, age at last use or time since last use among users were not associated with melanoma risk.
Use of formulations with high doses of estrogen (50 μg of EE) was positively associated with melanoma risk, even after adjustment (HR = 1.27, CI = 1.04-1.56). However, there was no evidence of a dose-response relationship across categories of increasing doses of estrogen in formulations (low, medium, high), and no other type of formulation was associated with melanoma risk.
Results were unchanged when models were additionally adjusted for parity, menopausal status, age at menarche, menstrual cycle length, use of other hormonal treatments, gynecologic follow-up, height, BMI, education, income, marital status, or smoking (data not shown).
When HRs were computed for each generation stratum (born <1930, 1930-1934, 1935-1939, 1940-1945 and >1945), we found a stronger association between OC use and melanoma risk among women born between 1930 and 1935 (HR = 1.68, CI = 1.00-2.81 in models adjusted for pigmentary traits, residential UV exposure and family history of skin cancer), although no heterogeneity was detected across generations (p homogeneity = 0.59).
We found no effect modification of the association between OC use and melanoma risk by pigmentary traits, use of other hormonal treatments, height, and socio-economic factors. However, the association between OC use and melanoma risk was stronger in women working in the National Education system but who were not teachers (HR = 1.69, CI = 1.05-2.71 in adjusted model) than in teachers (HR = 1.06, CI = 0.85-1.32) (p interaction = 0.07 in non-adjusted models, and p interaction = 0.08 in adjusted models).
In competing-risk analyses considering histologic type (superficial spreading, lentigo maligna, nodular, acrolentiginous and other) and melanoma site (head and neck, trunk, upper or lower limbs), associations were positive for all types and sites, except the trunk (Table 4 ) and no heterogeneity was detected across subtypes (p homogeneity = 0.54) or sites (p homogeneity = 0.23).
In the E3N-SunExp population, the association between OC use and melanoma risk was positive although not statistically significant. Adjustment for residential and recreational UV exposure did not substantially modify the results (data not tabulated).
When investigating the potential associations between UV exposure behaviors and OC use among controls, we found that even after adjustment for age and stratification on year of birth, OC users were more likely to report tanning bed use compared with non-users (OR = 1.14, CI = 1.01-1.29). They were also more likely to report higher numbers of sunburns since age 25 (p trend = 0.05). Finally, OC use was positively associated with the sunscreen use at ages 15-25 (p trend = 0.04) and 25 years (p trend = 0.01), and inversely associated with residential hours of UV exposure (p trend < 0.01), but these associations were no longer statistically significant after adjusting for age and year of birth. We found no association with hours of sun exposure or UV scores, and no interaction between sun exposure behaviors and pigmentary traits in relation to OC use.
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DISCUSSION
In this large prospective cohort, we found a positive association between OC use and melanoma risk, which was restricted to long-term users and users of OCs containing high doses of estrogen. We found no effect modification of sun exposure on the relation between OC use and melanoma risk. However, OC users were more likely to report use of tanning beds and Duration of OC use (years), mean (SD) 2 7.3 (6.0)
Age at start of OC (years), mean (SD) 3 28.7 (6.5) Age at last OC use (years), mean (SD) 4,5 38.2 (8.1) 1 11,669 missing values among ever users. 2 17,162 missing values among ever users. 3 15,889 missing values among ever users. 4 Among past users. 5 18,123 missing values among ever users Figure 1 . Spline regression of the association between duration of OC use at the end of follow-up and melanoma risk (obtained by spline regression with four knots [0, 2.5, 6 and 11 years] and never OC use as the reference), E3N cohort (n = 79,365). of sunscreen in adulthood, although other sun exposure behaviors were not associated with OC use. Overall, these results contrast with the findings from three meta-analyses that suggest no influence of OC use on melanoma risk in women overall. [23] [24] [25] Duration of OC use was associated with a higher risk of melanoma among users in our study, especially after 7 years of use. In most previous studies considering duration of use, no relation was found, except in a prospective cohort in which a positive association was observed in women who used OCs for at least 10 years, but for current use only. 38 In E3N, information on OC exposure was very detailed, and we had the opportunity to study different types of hormones used. Most women took multiple OC types in their lifetime, making it difficult to analyze each type of treatment taken exclusively. However, when analyzing each type of OC while adjusting simultaneously for other types, formulations with high doses of estrogen were positively associated with melanoma risk, but not with other formulations. This is consistent with the positive association found in women using OCs with high cumulative daily doses in a previous casecontrol study. 11 However, our results do not support a doseresponse relationship since we did not observe any trend across increasing doses. This pattern of association may have at least two explanations. First, OCs with high doses of estrogen were the first ones on the market, and in the cohort a majority of OC users reported to have ever used this type of OCs, suggesting a higher statistical power in the analyses compared with other OCs. Second, as older generations are more likely to have used OCs with high estrogen doses, it could be hypothesized that the association with high doses of estrogen is due to a cohort effect. However, in our study population, type of OC was missing for a large fraction of participants among older generations, and so this hypothesis cannot be verified. The 'high dose of estrogens' category was more frequent in women from recent birth cohorts, i.e. who were born >1945.
The E3N-SunExp nested case-control study enabled us to consider detailed data on both residential and recreational sun exposure. While we found no association between OC use and lifetime hours of sun exposure or UV score, we observed that OC use was positively associated with sunburns after 25 years and tanning bed use, even after adjusting for age and year of birth. However, adjusting for sunburns and tanning beds had no substantial effect on the relation between OC use and melanoma risk in our study. Nevertheless, these observations underline the importance of considering the potential confounding effect of sun exposure behaviors when exploring the Model adjusted for age and stratified according to year of birth. 2 Model additionally adjusted for residential UV exposure at birth and at inclusion, pigmentary traits and family history of skin cancer. relation between OC use and melanoma risk, and the need to further explore the sun exposure profile of OC users in future research.
It could be hypothesized that OC users might use the medical care system or perform skin self-examinations more frequently, and thus be more likely to be diagnosed or to have their pigmented lesions removed. In our analysis, we used Pap smears as a proxy for gynecologic follow-up, but we did not observe any effect modification with this parameter. Also, using oral hormones for contraception was more frequent among educated and wealthy women a few decades ago, which could suggest a bias related to socioeconomic factors. Such a bias would be less likely nowadays since the pill is now widely used regardless of socioeconomic status in the general population. 39 Nevertheless, we found no impact of socioeconomic factors on the relation between OC use and melanoma risk. OC use seemed to be more strongly associated with melanoma risk among women working in the National Education system but who were not teachers, which underlines the importance of repeating this analysis in study populations that are more representative of the general population.
Our study has several strengths, particularly its sample sizeit is currently the largest prospective study on the association between OC use and melanoma risk to date; the ability to study different melanoma sites and types; the availability of detailed data on OC use over lifetime, enabling us to study different types of hormonal preparations; and the availability of sun exposure data that enabled us to explore the potential confounding or modification effects of sun exposure behaviors on the association between OC use and melanoma risk. We were also able to explore the sun exposure profile of OC users, which has never been investigated to date to our knowledge. However, several limitations need to be considered in the interpretation of our findings. The major limitation is the relatively high age of E3N participants at cohort inclusion (40-65 years): the long delay between women's OC exposure and our ability to observe incident melanoma cases implies that we were only able to study long-term effects of OCs, as opposed to current use of OCs and their potential shorterterm effects on melanoma risk. This is an important limitation considering that sex hormones were recently suggested to affect the risk of early-onset melanoma. 40, 43 Another, more moderate limitation, is the overall higher socioeconomic status of the cohort, with a high proportion of teachers. However, this is also an advantage in terms of reliability of self-reported features in this highly-motivated population. 41 Finally, the potential effects of UV exposure might not have been fully addressed in our models, since UV was estimated through proxy measures instead of objectively validated questionnaires, as recently developed. 42 Nevertheless, an asset of our study was to consider lifetime sun exposure.
Conclusion
We found a positive association between OC use and melanoma risk, which was restricted to long-term users and users of OCs containing high doses of estrogens. Our results also suggest a specific profile of OC users regarding their attitude towards tanning. Therefore, we cannot exclude that the observed relation between OC use and melanoma risk, which has been debated in the literature for almost 40 years, could relate to particular sun exposure behaviors in users. Further research is thus critical to increase our understanding of the risk profile of women diagnosed with melanoma, and to question the hypothesis of a hormonal influence on melanoma risk. This research should use prospective cohort data spanning younger ages at melanoma diagnosis, and include social and behavioral description of OC users.
